2012 OMF Conference - Walther and Maetzold on
For more information, please go to http://www.ocularmelanoma.org.
This talk from the 2012 OMF Conference is titled "Prognostic testing: What do the tests offer? When do I have to decide?" The talk was given by Susan Walther, MS, CGC, University of Pennsylvania Genetic Diagnostic Laboratory abd Derek Maetzold, President & CEO, Castle Biosciences Inc.
Susan Walther is a Genetic Counselor at the Genetic Diagnostic Laboratory, Department of Genetics, University of Pennsylvania, Philadelphia, PA. Ms. Walther works in the laboratory that offers genetic SNP-array based analysis of ocular melanoma tumors and provides post-test counseling for the risk assessment. She is certified by the American Board of Genetic Counseling (Genetic Counselor).
Mr. Maetzold is founder, President, CEO, and Board member of Castle Biosciences, Inc. He has been a leader in biopharmaceuticals for 24 years, working in increasing leadership roles at Encysive Pharmaceuticals, Schering Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz (now Novartis). Derek started in field sales, completed assignments in marketing, new product development, business development, commercialization strategy and completed his tenure prior to Castle Biosciences at Encysive as Officer and Vice President, Marketing and Sales. Derek attended George Mason University, where he received a BS in Biology before completing additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside. Castle Biosciences is a biomarker based cancer diagnostics company that is committed to bringing the promise of personalized medicine to underserved orphan diseases. It focuses its our efforts in aggressive, underserved orphan cancer markets where it hopes to assist the oncologist in achieving greater outcomes for their patients by providing them with diagnostic information that aids their decision making.
-
Category
No comments found